Skip to main content
Top
Published in: Indian Journal of Surgical Oncology 2/2019

01-06-2019 | Colorectal Cancer | Case Report

Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon

Authors: Saheer N, Prasanth Penumadu, Ashwani Kumar Sachdeva, Pavneet Singh Kohli

Published in: Indian Journal of Surgical Oncology | Issue 2/2019

Login to get access

Excerpt

Gastrointestinal malignancy accounts for the most common cause of extragenital primary spreading to female genital tract with colorectal carcinoma leading among them [1]. Ovary and vagina are the most common sites for spread. Synchronous presentation occurs more frequently than metachronous lesions [2]. Isolated tumor deposit to one or more genital organs is rare. The present case discusses regarding the metachronous presentation of carcinoma colon to multiple genital organs. …
Literature
1.
go back to reference Mutter GL, Prat J (2014) Pathology of the female reproductive tract. Elsevier Health Sciences 2821 p Mutter GL, Prat J (2014) Pathology of the female reproductive tract. Elsevier Health Sciences 2821 p
2.
go back to reference Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C (2012 Sep) Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer 11(3):191–194CrossRefPubMed Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C (2012 Sep) Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer 11(3):191–194CrossRefPubMed
4.
go back to reference Omranipour R, Abasahl A (2009) Ovarian metastases in colorectal cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 19(9):1524–1528CrossRef Omranipour R, Abasahl A (2009) Ovarian metastases in colorectal cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 19(9):1524–1528CrossRef
5.
go back to reference Segelman J, Flöter-Rådestad A, Hellborg H, Sjövall A, Martling A (2010) Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 97(11):1704–1709CrossRefPubMed Segelman J, Flöter-Rådestad A, Hellborg H, Sjövall A, Martling A (2010) Epidemiology and prognosis of ovarian metastases in colorectal cancer. Br J Surg 97(11):1704–1709CrossRefPubMed
7.
go back to reference Kumar NB, Hart WR (1982 Nov) Metastases to the uterine corpus from extragenital cancers. A clinicopathologic study of 63 cases. Cancer 50(10):2163–2169CrossRefPubMed Kumar NB, Hart WR (1982 Nov) Metastases to the uterine corpus from extragenital cancers. A clinicopathologic study of 63 cases. Cancer 50(10):2163–2169CrossRefPubMed
8.
go back to reference Matsuura M, et al (2014) Metastatic carcinoma of the uterine cervix from rectal carcinoma: a case report and review of the literature. Open Journal of Obstetrics and Gynecology 4:617–620 Matsuura M, et al (2014) Metastatic carcinoma of the uterine cervix from rectal carcinoma: a case report and review of the literature. Open Journal of Obstetrics and Gynecology 4:617–620
9.
go back to reference JK-PRACTITIONER JAN-MAR 2011 - jabt11i1p99.pdf JK-PRACTITIONER JAN-MAR 2011 - jabt11i1p99.pdf
10.
11.
go back to reference Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. (2011) Cetuximab Plus Irinotecan, Fluorouracil, and leucovorin as first-Line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21502544. Accessed 23 Nov 2018 Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. (2011) Cetuximab Plus Irinotecan, Fluorouracil, and leucovorin as first-Line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011–9. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​21502544. Accessed 23 Nov 2018
12.
go back to reference Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9):1803–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15677699. Accessed 23 Nov 2018 Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9):1803–10. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15677699. Accessed 23 Nov 2018
13.
go back to reference Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. 2015 Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25989278. Accessed 23 Nov 2018 Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, et al. 2015 Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112(12):1888–94. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25989278. Accessed 23 Nov 2018
14.
go back to reference Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V 2017 The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87–98. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27907852. Accessed 23 Nov 2018 Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V 2017 The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87–98. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27907852. Accessed 23 Nov 2018
15.
go back to reference Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. 2017 Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28734759. Accessed 23 Nov 2018 Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, et al. 2017 Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–91. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28734759. Accessed 23 Nov 2018
16.
go back to reference Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. 2016 Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17(6):738–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27108243. Accessed 23 Nov 2018 Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. 2016 Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17(6):738–46. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27108243. Accessed 23 Nov 2018
Metadata
Title
Isolated Metastases to Multiple Genital Organs: a Curious Case of Metachronous Spread of Carcinoma Colon
Authors
Saheer N
Prasanth Penumadu
Ashwani Kumar Sachdeva
Pavneet Singh Kohli
Publication date
01-06-2019
Publisher
Springer India
Published in
Indian Journal of Surgical Oncology / Issue 2/2019
Print ISSN: 0975-7651
Electronic ISSN: 0976-6952
DOI
https://doi.org/10.1007/s13193-018-0855-2

Other articles of this Issue 2/2019

Indian Journal of Surgical Oncology 2/2019 Go to the issue